Trial Profile
A Fixed-Sequence, Open-Label Study to Determine the Activity of SCH717454 as Assessed by Positron Emission Tomography in Subjects With Relapsed or Recurrent Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Robatumumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 16 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.